As of April 26, 2023, around 81.3 percent of the U.S. population had received at least one dose of a COVID-19 vaccination. This statistic shows the percentage of the population in the United States who had been given a COVID-19 vaccination as of April 26, 2023, by state or territory.

As part of an ongoing partnership with the Census Bureau, the National Center for Health Statistics (NCHS) recently added questions to assess the prevalence of post-COVID-19 conditions (long COVID), on the experimental Household Pulse Survey. This 20-minute online survey was designed to complement the ability of the federal statistical system to rapidly respond and provide relevant information about the impact of the coronavirus pandemic in the U.S. Data collection began on April 23, 2020. Beginning in Phase 3.5 (on June 1, 2022), NCHS included questions about the presence of symptoms of COVID that lasted three months or longer. Phase 3.5 will continue with a two-weeks on, two-weeks off collection and dissemination approach. Estimates on this page are derived from the Household Pulse Survey and show the percentage of adults aged 18 and over who a) as a proportion of the U.S. population, the percentage of adults who EVER experienced post-COVID conditions (long COVID). These adults had COVID and had some symptoms that lasted three months or longer; b) as a proportion of adults who said they ever had COVID, the percentage who EVER experienced post-COVID conditions; c) as a proportion of the U.S. population, the percentage of adults who are CURRENTLY experiencing post-COVID conditions. These adults had COVID, had long-term symptoms, and are still experiencing symptoms; d) as a proportion of adults who said they ever had COVID, the percentage who are CURRENTLY experiencing post-COVID conditions; and e) as a proportion of the U.S. population, the percentage of adults who said they ever had COVID.

As of June 13, 2023, there have been almost 768 million cases of coronavirus (COVID-19) worldwide. The disease has impacted almost every country and territory in the world, with the United States confirming around 16 percent of all global cases.

COVID-19: An unprecedented crisis Health systems around the world were initially overwhelmed by the number of coronavirus cases, and even the richest and most prepared countries struggled. In the most vulnerable countries, millions of people lacked access to critical life-saving supplies, such as test kits, face masks, and respirators. However, several vaccines have been approved for use, and more than 13 billion vaccine doses had already been administered worldwide as of March 2023.

The coronavirus in the United Kingdom Over 202 thousand people have died from COVID-19 in the UK, which is the highest number in Europe. The tireless work of the National Health Service (NHS) has been applauded, but the country’s response to the crisis has drawn criticism. The UK was slow to start widespread testing, and the launch of a COVID-19 contact tracing app was delayed by months. However, the UK’s rapid vaccine rollout has been a success story, and around 53.7 million people had received at least one vaccine dose as of July 13, 2022.

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

As of December 23, 2022, around 80 percent of the population of the United States had been given at least one dose of a COVID-19 vaccination. This statistic shows the percentage of population in select countries and territories worldwide that had received a COVID-19 vaccination as of December 23, 2022.

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-Citywide/6859-spec. COVID-19 vaccinations administered to Chicago residents based on the reported race-ethnicity and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). Vaccination Status Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine. ·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received. ··People with an original booster dose: Number of people who have a completed vaccine series and have received at least one additional monovalent dose. This includes people who received a monovalent booster dose and immunocompromised people who received an additional primary dose of COVID-19 vaccine. Monovalent doses were created from the original strain of the virus that causes COVID-19. People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains. Weekly cumulative totals by vaccination status are shown for each combination of race-ethnicity and age group. Note that each age group has a row where race-ethnicity is "All" so care should be taken when summing rows. Vaccinations are counted based on the date on which they were administered. Weekly cumulative totals are reported from the week ending Saturday, December 19, 2020 onward (after December 15, when vaccines were first administered in Chicago) through the Saturday prior to the dataset being updated. Population counts are from the U.S. Census Bureau American Community Survey (ACS) 2019 1-year estimates. For some of the age groups by which COVID-19 vaccine has been authorized in the United States, race-ethnicity distributions were specifically reported in the ACS estimates. For others, race-ethnicity distributions were estimated by the Chicago Department of Public Health (CDPH) by weighting the available race-ethnicity distributions, using proportions of constituent age groups. Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity) who have each vaccination status as of the date, divided by the estimated number of Chicago residents in each subgroup. Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group. All coverage percentages are capped at 99%. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. CDPH uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Data reported in I-CARE only include doses administered in Illinois and some doses administered outside of Illinois reported historically by Illinois providers. Doses administered by the federal Bureau of Prisons and Department of Defense are also not currently reported in I-CARE. The Veterans Health Administration began reporting doses in I-CARE beginning September 2022. Due to people receiving vaccinations that are not recorded in I-CARE that c

According to a survey conducted from August 20 to September 16, 2024, approximately 35 percent of U.S. adults aged between 50 and 59 years who had COVID-19 experienced Long COVID, the highest share compared to other age groups. Individuals aged 40 to 49 followed, with 34 percent experiencing Long COVID symptoms. This statistic shows the percentage of adults who had COVID-19 and ever experienced Long COVID in the United States from August 20 to September 16, 2024, by age group.

These tables will stop being updated after June 1, 2023. COVID-19 vaccination reporting is expected to resume when a new COVID-19 vaccination formulation is authorized. As 4/22/2023, CDC recommends bivalent vaccine for everyone regardless of age and whether or not the person has had prior monovalent vaccine. This table shows the cumulative number and percentage of people who have received an updated (bivalent) COVID-19 vaccination by race/ethnicity and age group for people 5 years and over. • Data are reported weekly on Thursday and include doses administered to Saturday of the previous week. • All data in this report are preliminary. Data for previous weeks may be changed because of delays in reporting, deduplication, or correction of errors. • The table groups people based on their current age and excludes people known to be deceased. • The analyses here are based on data reported to CT WiZ which is the immunization information system for CT. Connecticut COVID-19 Vaccine Program providers are required to report to CT WiZ all COVID-19 doses administered in CT including to CT residents and to residents of other jurisdictions. CT Wiz also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT WiZ electronically (currently: RI, NJ, New York City, DE, Philadelphia, NV, Indian Health Service, Department of Veterans Affairs (doses administered since 11/2022)). Electronic data exchange is being added jurisdiction-by-jurisdiction. Once a jurisdiction is added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed. • Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*. • Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple races. A vaccine coverage percentage cannot be calculated for people classified as NH (non-Hispanic) Other race or NH Unknown race since there are no population size estimates for these groups. Data quality assurance activities suggest that in at least some cases NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the classification of records as NH Unknown Race or NH Other Race. • Cumulative percentage estimates have been capped at 100%. Observed percentages may be higher than 100% for multiple reasons, inaccuracies in the census denominators or reporting errors. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

NOTE: As of 2/16/2023 this table is no longer being updated. For information on COVID-19 Updated (Bivalent) Booster Coverage, go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Race/8267-bg4w.

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by age at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This table shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 by race / ethnicity and age group.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple races.

A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities suggest that in at least some cases NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the classification of records as NH Unknown Race or NH Other Race.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: This dataset takes the place of the original "COVID-19 Vaccinations by Race/Ethnicity" dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/xkga-ifz3 ), which will not be updated after 5/20/2021 and “COVID-19 Vaccinations by Race / Ethnicity” dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/ybkg-w5x2), which will not be updated after 10/20/2021.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

It was estimated that around 20 percent of those with underlying health conditions who had COVID-19 in the United States from January 22 to May 30, 2020 died from the disease, compared to just 2 percent of COVID-patients without underlying health conditions. Underlying health conditions such as cardiovascular disease, chronic lung disease, or diabetes greatly increase the chance of death due to COVID-19. This statistic shows the percentage of people in the U.S. who had COVID-19 from January 22 to May 30, 2020 with and without underlying health conditions who died, by age.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

As of May 2, 2023, there were roughly 687 million global cases of COVID-19. Around 660 million people had recovered from the disease, while there had been almost 6.87 million deaths. The United States, India, and Brazil have been among the countries hardest hit by the pandemic.

The various types of human coronavirus The SARS-CoV-2 virus is the seventh known coronavirus to infect humans. Its emergence makes it the third in recent years to cause widespread infectious disease following the viruses responsible for SARS and MERS. A continual problem is that viruses naturally mutate as they attempt to survive. Notable new variants of SARS-CoV-2 were first identified in the UK, South Africa, and Brazil. Variants are of particular interest because they are associated with increased transmission.

Vaccination campaigns Common human coronaviruses typically cause mild symptoms such as a cough or a cold, but the novel coronavirus SARS-CoV-2 has led to more severe respiratory illnesses and deaths worldwide. Several COVID-19 vaccines have now been approved and are being used around the world.

NOTE: This dataset has been retired and marked as historical-only.

Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age.

Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine.

Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS).

Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death.

Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test.

CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset.

Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000.

Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people.

Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population.

Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchic

Global Covid-19 Data

Global Covid-19 data on cases, deaths, vaccinations, and more

By Valtteri Kurkela [source]

About this dataset

The dataset is constantly updated and synced hourly to ensure up-to-date information. With over several columns available for analysis and exploration purposes, users can extract valuable insights from this extensive dataset.

Some of the key metrics covered in the dataset include:

1. Vaccinations: The dataset covers total vaccinations administered worldwide as well as breakdowns of people vaccinated per hundred people and fully vaccinated individuals per hundred people.

2. Testing & Positivity: Information on total tests conducted along with new tests conducted per thousand people is provided. Additionally, details on positive rate (percentage of positive Covid-19 tests out of all conducted) are included.

3. Hospital & ICU: Data on ICU patients and hospital patients are available along with corresponding figures normalized per million people. Weekly admissions to intensive care units and hospitals are also provided.

4. Confirmed Cases: The number of confirmed Covid-19 cases globally is captured in both absolute numbers as well as normalized values representing cases per million people.

5.Confirmed Deaths: Total confirmed deaths due to Covid-19 worldwide are provided with figures adjusted for population size (total deaths per million).

6.Reproduction Rate: The estimated reproduction rate (R) indicates the contagiousness of the virus within a particular country or region.

7.Policy Responses: Besides healthcare-related metrics, this comprehensive dataset includes policy responses implemented by countries or regions such as lockdown measures or travel restrictions.

8.Other Variables of InterestThe data encompasses various socioeconomic factors that may influence Covid-19 outcomes including population density,membership in a continent,gross domestic product(GDP)per capita;

For demographic factors: -Age Structure : percentage populations aged 65 and older,aged (70)older,median age -Gender-specific factors: Percentage of female smokers -Lifestyle-related factors: Diabetes prevalence rate and extreme poverty rate

1. Excess Mortality: The dataset further provides insights into excess mortality rates, indicating the percentage increase in deaths above the expected number based on historical data.

The dataset consists of numerous columns providing specific information for analysis, such as ISO code for countries/regions, location names,and units of measurement for different parameters.

Overall,this dataset serves as a valuable resource for researchers, analysts, and policymakers seeking to explore various aspects related to Covid-19

How to use the dataset

Introduction:

• Understanding the Basic Structure:

  • The dataset consists of various columns containing different data related to vaccinations, testing, hospitalization, cases, deaths, policy responses, and other key variables.
  • Each row represents data for a specific country or region at a certain point in time.

• Selecting Desired Columns:

  • Identify the specific columns that are relevant to your analysis or research needs.
  • Some important columns include population, total cases, total deaths, new cases per million people, and vaccination-related metrics.

• Filtering Data:

  • Use filters based on specific conditions such as date ranges or continents to focus on relevant subsets of data.
  • This can help you analyze trends over time or compare data between different regions.

• Analyzing Vaccination Metrics:

  • Explore variables like total_vaccinations, people_vaccinated, and people_fully_vaccinated to assess vaccination coverage in different countries.
  • Calculate metrics such as people_vaccinated_per_hundred or total_boosters_per_hundred for standardized comparisons across populations.

• Investigating Testing Information:

  • Examine columns such as total_tests, new_tests, and tests_per_case to understand testing efforts in various countries.
  • Calculate rates like tests_per_case to assess testing efficiency or identify changes in testing strategies over time.

• Exploring Hospitalization and ICU Data:

  • Analyze variables like hosp_patients, icu_patients, and hospital_beds_per_thousand to understand healthcare systems' strain.
  • Calculate rates like icu_patients_per_million or hosp_patients_per_million for cross-country comparisons.

• Assessing Covid-19 Cases and Deaths:

  • Analyze variables like total_cases, new_ca...

Updates

• Notice of data discontinuation: Since the start of the pandemic, AP has reported case and death counts from data provided by Johns Hopkins University. Johns Hopkins University has announced that they will stop their daily data collection efforts after March 10. As Johns Hopkins stops providing data, the AP will also stop collecting daily numbers for COVID cases and deaths. The HHS and CDC now collect and visualize key metrics for the pandemic. AP advises using those resources when reporting on the pandemic going forward.

  • CDC Weekly case and death counts (national and state level)
  • CDC County level cases and deaths
  • HHS New hospital admissions
  • CDC NowCast COVID variant proportions (national and regional level)

• April 9, 2020

  • The population estimate data for New York County, NY has been updated to include all five New York City counties (Kings County, Queens County, Bronx County, Richmond County and New York County). This has been done to match the Johns Hopkins COVID-19 data, which aggregates counts for the five New York City counties to New York County.

• April 20, 2020

  • Johns Hopkins death totals in the US now include confirmed and probable deaths in accordance with CDC guidelines as of April 14. One significant result of this change was an increase of more than 3,700 deaths in the New York City count. This change will likely result in increases for death counts elsewhere as well. The AP does not alter the Johns Hopkins source data, so probable deaths are included in this dataset as well.

• April 29, 2020

  • The AP is now providing timeseries data for counts of COVID-19 cases and deaths. The raw counts are provided here unaltered, along with a population column with Census ACS-5 estimates and calculated daily case and death rates per 100,000 people. Please read the updated caveats section for more information.

• September 1st, 2020

  • Johns Hopkins is now providing counts for the five New York City counties individually.

• February 12, 2021

  • The Ohio Department of Health recently announced that as many as 4,000 COVID-19 deaths may have been underreported through the state’s reporting system, and that the "daily reported death counts will be high for a two to three-day period."
  • Because deaths data will be anomalous for consecutive days, we have chosen to freeze Ohio's rolling average for daily deaths at the last valid measure until Johns Hopkins is able to back-distribute the data. The raw daily death counts, as reported by Johns Hopkins and including the backlogged death data, will still be present in the new_deaths column.

• February 16, 2021

  - Johns Hopkins has reconciled Ohio's historical deaths data with the state.

  Overview

The AP is using data collected by the Johns Hopkins University Center for Systems Science and Engineering as our source for outbreak caseloads and death counts for the United States and globally.

The Hopkins data is available at the county level in the United States. The AP has paired this data with population figures and county rural/urban designations, and has calculated caseload and death rates per 100,000 people. Be aware that caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.

This data is from the Hopkins dashboard that is updated regularly throughout the day. Like all organizations dealing with data, Hopkins is constantly refining and cleaning up their feed, so there may be brief moments where data does not appear correctly. At this link, you’ll find the Hopkins daily data reports, and a clean version of their feed.

The AP is updating this dataset hourly at 45 minutes past the hour.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Queries

Use AP's queries to filter the data or to join to other datasets we've made available to help cover the coronavirus pandemic

• Filter cases by state here

• Rank states by their status as current hotspots. Calculates the 7-day rolling average of new cases per capita in each state: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=481e82a4-1b2f-41c2-9ea1-d91aa4b3b1ac

• Find recent hotspots within your state by running a query to calculate the 7-day rolling average of new cases by capita in each county: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=b566f1db-3231-40fe-8099-311909b7b687&showTemplatePreview=true

• Join county-level case data to an earlier dataset released by AP on local hospital capacity here. To find out more about the hospital capacity dataset, see the full details.

• Pull the 100 counties with the highest per-capita confirmed cases here

• Rank all the counties by the highest per-capita rate of new cases in the past 7 days here. Be aware that because this ranks per-capita caseloads, very small counties may rise to the very top, so take into account raw caseload figures as well.

Interactive

The AP has designed an interactive map to track COVID-19 cases reported by Johns Hopkins.

@(https://datawrapper.dwcdn.net/nRyaf/15/)

Interactive Embed Code

<iframe title="USA counties (2018) choropleth map Mapping COVID-19 cases by county" aria-describedby="" id="datawrapper-chart-nRyaf" src="https://datawrapper.dwcdn.net/nRyaf/10/" scrolling="no" frameborder="0" style="width: 0; min-width: 100% !important;" height="400"></iframe><script type="text/javascript">(function() {'use strict';window.addEventListener('message', function(event) {if (typeof event.data['datawrapper-height'] !== 'undefined') {for (var chartId in event.data['datawrapper-height']) {var iframe = document.getElementById('datawrapper-chart-' + chartId) || document.querySelector("iframe[src*='" + chartId + "']");if (!iframe) {continue;}iframe.style.height = event.data['datawrapper-height'][chartId] + 'px';}}});})();</script>

Caveats

• This data represents the number of cases and deaths reported by each state and has been collected by Johns Hopkins from a number of sources cited on their website.
• In some cases, deaths or cases of people who've crossed state lines -- either to receive treatment or because they became sick and couldn't return home while traveling -- are reported in a state they aren't currently in, because of state reporting rules.
• In some states, there are a number of cases not assigned to a specific county -- for those cases, the county name is "unassigned to a single county"
• This data should be credited to Johns Hopkins University's COVID-19 tracking project. The AP is simply making it available here for ease of use for reporters and members.
• Caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.
• Population estimates at the county level are drawn from 2014-18 5-year estimates from the American Community Survey.
• The Urban/Rural classification scheme is from the Center for Disease Control and Preventions's National Center for Health Statistics. It puts each county into one of six categories -- from Large Central Metro to Non-Core -- according to population and other characteristics. More details about the classifications can be found here.

Johns Hopkins timeseries data - Johns Hopkins pulls data regularly to update their dashboard. Once a day, around 8pm EDT, Johns Hopkins adds the counts for all areas they cover to the timeseries file. These counts are snapshots of the latest cumulative counts provided by the source on that day. This can lead to inconsistencies if a source updates their historical data for accuracy, either increasing or decreasing the latest cumulative count. - Johns Hopkins periodically edits their historical timeseries data for accuracy. They provide a file documenting all errors in their timeseries files that they have identified and fixed here

Attribution

This data should be credited to Johns Hopkins University COVID-19 tracking project

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 12+ and age 5+ denominators have been uploaded as archived tables.

Starting June 30, 2021, the dataset has been reconfigured so that all updates are appended to one dataset to make it easier for API and other interfaces. In addition, historical data has been extended back to January 5, 2021.

This dataset shows full, partial, and at least 1 dose coverage rates by zip code tabulation area (ZCTA) for the state of California. Data sources include the California Immunization Registry and the American Community Survey’s 2015-2019 5-Year data.

This is the data table for the LHJ Vaccine Equity Performance dashboard. However, this data table also includes ZTCAs that do not have a VEM score.

This dataset also includes Vaccine Equity Metric score quartiles (when applicable), which combine the Public Health Alliance of Southern California’s Healthy Places Index (HPI) measure with CDPH-derived scores to estimate factors that impact health, like income, education, and access to health care. ZTCAs range from less healthy community conditions in Quartile 1 to more healthy community conditions in Quartile 4.

The Vaccine Equity Metric is for weekly vaccination allocation and reporting purposes only. CDPH-derived quartiles should not be considered as indicative of the HPI score for these zip codes. CDPH-derived quartiles were assigned to zip codes excluded from the HPI score produced by the Public Health Alliance of Southern California due to concerns with statistical reliability and validity in populations smaller than 1,500 or where more than 50% of the population resides in a group setting.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

For some ZTCAs, vaccination coverage may exceed 100%. This may be a result of many people from outside the county coming to that ZTCA to get their vaccine and providers reporting the county of administration as the county of residence, and/or the DOF estimates of the population in that ZTCA are too low. Please note that population numbers provided by DOF are projections and so may not be accurate, especially given unprecedented shifts in population as a result of the pandemic.